Akero Therapeutics Reports Significant Histological Improvements in Phase 2b HARMONY Study at Week 96
Akero Therapeutics, a leading biotechnology company, recently released a press release highlighting the encouraging results of their Phase 2b HARMONY study. The study evaluated the efficacy and safety of EFX, the company’s investigational drug, in patients with nonalcoholic steatohepatitis (NASH).
NASH is a liver disease characterized by the build-up of fat in the liver, leading to inflammation and fibrosis. It is a growing concern globally, with no approved treatments currently available. Akero Therapeutics has been working tirelessly to develop a potential solution for this unmet medical need.
According to the press release, the study showed statistically significant histological improvements at week 96 in patients who received EFX treatment. Specifically, the 50mg EFX group demonstrated a 75% improvement in fibrosis without worsening of MASH, while the 28mg EFX group showed a 46% improvement. Comparatively, the placebo group had a 24% improvement rate. These results indicate a substantial and promising step forward in the treatment of NASH.
The improvement in fibrosis observed in the EFX groups is particularly noteworthy. Fibrosis refers to the scarring of liver tissue, which can progress to cirrhosis and liver failure in advanced stages. The fact that both the 50mg and 28mg EFX groups demonstrated a one-stage improvement in fibrosis without worsening of MASH is a significant achievement. Furthermore, the improvement rates in the EFX groups were approximately three-fold and two-fold higher than the placebo group, respectively.
These findings highlight the potential therapeutic benefits of EFX in treating NASH, offering hope to millions of patients suffering from this progressive liver disease. The study also reinforces Akero Therapeutics’ commitment to developing innovative and effective treatments that can significantly improve patient outcomes.
Dr. Mark Mallon, CEO of Akero Therapeutics, expressed his excitement about the results, stating, The significant histological improvements observed in our HARMONY study validate the potential of EFX as a treatment for NASH. We are encouraged by these findings and will continue our efforts to advance this investigational drug through further clinical development.
As the company moves forward, it plans to conduct additional studies to further evaluate the safety and efficacy of EFX. Akero Therapeutics aims to provide clinicians and patients with a much-needed treatment option for NASH, addressing the significant unmet medical need in this field.
In conclusion, Akero Therapeutics has reported promising results from their Phase 2b HARMONY study, demonstrating significant histological improvements in patients with NASH. The one-stage improvement in fibrosis without worsening of MASH observed in the EFX groups offers hope for effective NASH treatment options. These findings mark a significant milestone in the development of a potential therapy for NASH, and Akero Therapeutics remains committed to advancing this promising investigational drug through further clinical trials.
Comments